Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
Location: United States
Total raised: $50M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.03.2026 | Series C | $50M | Engine Ven... |
Mentions in press and media 3
| Date | Title | Description |
| 29.03.2026 | Terrestrial Bio Secures $50M, Pioneers Future of Drug Delivery | Terrestrial Bio secured $50M in Series C funding, rebranding from Vaxess Technologies. The biotech leader pioneers a microarray patch (MAP) platform. This innovative technology revolutionizes drug delivery. It enables self-administration of... |
| 27.03.2026 | Terrestrial Bio: $50 Million Raised For Microarray Patch Therapeutics Platform And Rebrand From Vaxess Technologies | Terrestrial Bio, a biotech company developing a microarray patch platform for therapeutics, announced it has raised $50 million in Series C funding and rebranded from Vaxess Technologies. The funding round was led by RA Capital, with partic... |
| 26.03.2026 | Terrestrial Bio Raises $50M in Series C Funding | Terrestrial Bio (formerly Vaxess Technologies, Inc.), a Woburn, MA-based biotech company developing a microarray patch (MAP) platform capable of delivering a wide range of therapies, raised $50M in Series C funding. The round was led by RA ... |